Jinfeng Yang

Mr. Jinfeng Yang

Chengdu Sport University, Chengdu, Sichuan, China
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Jinfeng YangJinfeng Yang
Jinfeng Yang
YWYang Wang
Yang Wang
JCJianxin chen
Jianxin chen
JYJinqi Yang
Jinqi Yang
NLNa Li
Na Li
YLYuanpeng Liao
Yuanpeng Liao
FIFA11+ Kids is a warm-up program specially designed to prevent football injuries in children. This systematic review and meta-analysis aimed to summarize the effects of FIFA11+ Kids on injury prevention in young football players. PubMed, Web of Science, Embase, Cochrane Library, and China National Knowledge Infrastructure were searched from 1 January 2016 to 24 August 2022. The primary outcome was overall injuries, and the secondary outcomes were severe, ankle, knee, and lower extremity injuries. Risk ratios (RRs) were calculated for each outcome. Methodological quality was assessed using the Physiotherapy Evidence Database (PEDro) scale. A total of 230 articles were screened, 6 of which were finally included in the meta-analysis. Compared with normal warm-up training, FIFA11+ Kids significantly reduced overall injury risk (RR = 0.52 [95% CI, 0.44–0.62]; p < 0.00001), severe injury risk (RR = 0.33 [95% CI, 0.18–0.61]; p = 0.0004), lower extremity injury risk (RR = 0.51 [95% CI, 0.41–0.65]; p < 0.00001), knee injury risk (RR = 0.45 [95% CI, 0.29–0.72]; p = 0.0009), and ankle injury risk (RR = 0.56 [95% CI, 0.35–0.89]; p = 0.01) in young football players. FIFA11+ Kids was found to be an effective approach to decrease the injury risk among young football players, which is worth generalizing extensively.

13 December 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
Jinfeng YangJinfeng Yang
Jinfeng Yang
YWYang Wang
Yang Wang
SHSheng He
Sheng He
XPXiao Peng
Xiao Peng
CWChun Wang
Chun Wang
YLYuanpeng Liao
Yuanpeng Liao
Introduction: COVID-19 has posed a serious threat to people worldwide, especially the older adults, since its discovery. Tai Chi as a traditional Chinese exercisethat belongs to traditional Chinese medicine has proven its effectiveness against COVID-19. However, no high-quality evidence is found on the dose–response relationships between Tai Chi and clinical outcomes in patients with COVID-19. This study will evaluate and determine the clinical evidence of Tai Chi as a treatment in elderly patients with COVID-19. Methods and analysis: The following electronic bibliographical databases including PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure, VIP Database and Wanfang Database will be screened from their inception date to 30 June 2022. All eligible randomised controlled trials or controlled clinical trials related to Tai Chi for elderly patients with COVID-19 will be included. The primary outcomes are forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC) and FEV1/FVC ratio (FEV1%). The secondary outcomes are the time of main symptoms disappearance, length of hospital stay, serum levels of interleukin (IL)-6, IL-1b and tumour necrosis factor-α, and adverse event rate. Two independent reviewers will select the studies, extract the data, and analyse them on EndNote V.X9.0 and Stata V.12.1. The robust error meta-regression model will be used to establish the dose–response relationships between Tai Chi and clinical outcomes. The heterogeneity and variability will be analysed by I 2 and τ 2 statistics. Risk of bias, subgroup analysis and sensitivity analysis will also be performed. The quality of evidence will be assessed by the Grading of Recommendations Assessment, Development and Evaluation, and the risk of bias will be evaluated by using the Physiotherapy Evidence Database Scale. Ethics and dissemination: This study will review published data; thus, obtaining ethical approval and consent is unnecessary. The results will be disseminated through peer-reviewed publications. PROSPERO registration number: CRD42022327694.

20 August 2026 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
JXJipeng Xu
Jipeng Xu
PSPeijie Sun
Peijie Sun
Jinfeng YangJinfeng Yang
Jinfeng Yang
YZYani Zhu
Yani Zhu
YLYuanpeng Liao
Yuanpeng Liao
Introduction: Chronic postsurgical pain (CPSP) remains a major clinical challenge following total knee arthroplasty (TKA), with psychological maladaptation and persistent neuromuscular dysfunction considered key contributors to ongoing pain and disability. Pain neuroscience education (PNE) may improve maladaptive pain cognitions, whereas blood flow restriction training (BFRT) can enhance muscle function and induce exercise-related hypoalgesia. Although both interventions have shown potential benefits in chronic pain rehabilitation, no randomized controlled trial has investigated the combined efficacy of these two interventions in patients with CPSP after TKA. This study aims to determine whether combined PNE + BFRT produces greater improvements in pain and function in this population. Methods and analysis: This study is a single-blind, four-arm, parallel-group randomized controlled trial. A total of 148 participants will be randomly assigned (1:1:1:1) to the Control, PNE, BFRT, or combined PNE + BFRT group. PNE will be delivered in two structured sessions. BFRT involves a 12-week supervised low-load resistance training program. The primary outcome is the group-by-time interaction effect on KOOS₄ over time. Secondary outcomes include pain intensity (NRS), global perceived effect, pain distribution, psychological measures (HADS, PCS), physical performance (40-m fast-paced walk test, stair climb test, and 30-s chair stand test), and neuromuscular strength. Assessments will be conducted at baseline, post-intervention (12 weeks), and at 12-week, 24-week, and 36-week follow-ups. Data will be analyzed using linear mixed-effects models under the intention-to-treat principle. Ethics and dissemination: Ethics approval has been obtained from the Ethics Committee of the Chengdu Sport University, with permission number CDSUEC2026- 177. This study has been registered with the Chinese Clinical Trial Registry (ChiCTR2600125544). Written informed consent will be obtained from all participants prior to enrollment. Trial registration number: Chinese Clinical Trial Registry ChiCTR2600125544, registered on May 28, 2026.